TABLE 1.
Organism group (no. tested)/ antimicrobial agent | MIC50b | MIC90b | % Susceptible/resistanta |
|
---|---|---|---|---|
CLSI | EUCAST | |||
MRSA (5,000) | ||||
Telavancin | 0.12 | 0.25 | 100.0/—c | 100.0/ |
Vancomycin | 1 | 1 | 99.9/0.0 | 99.9/0.1 |
Teicoplanin | ≤2 | ≤2 | >99.9/<0.1 | 98.7/1.3 |
Daptomycin | 0.25 | 0.5 | 99.9/— | 99.9/0.1 |
Linezolid | 1 | 2 | >99.9/— | >99.9/<0.1 |
Quinupristin-dalfopristin | 0.5 | 1 | 99.5/0.2 | 99.5/0.2 |
Levofloxacin | >4 | >4 | 21.6/77.9 | 21.6/77.9 |
Erythromycin | >4 | >4 | 13.9/85.6 | 14.2/85.6 |
Clindamycin | ≤0.25 | >2 | 54.7/45.0 | 54.3/45.3 |
Gentamicin | ≤1 | >8 | 77.9/21.1 | 77.1/22.9 |
Tetracycline | ≤1 | >8 | 80.7/19.1 | 80.1/19.9 |
TMP/SMX | ≤0.5 | ≤0.5 | 92.4/7.6 | 92.4/7.6 |
MSSA (5,000) | ||||
Telavancin | 0.12 | 0.25 | 100.0/— | 100.0/— |
Vancomycin | 1 | 1 | 100.0/0.0 | 100.0/0.0 |
Teicoplanin | ≤2 | ≤2 | 100.0/0.0 | 99.9/0.1 |
Daptomycin | 0.25 | 0.5 | 100.0/— | 100.0/0.0 |
Linezolid | 2 | 2 | 100.0/— | 100.0/0.0 |
Quinupristin-dalfopristin | ≤0.25 | 0.5 | 99.9/0.0 | 99.9/0.0 |
Levofloxacin | ≤0.5 | ≤0.5 | 92.9/6.8 | 92.9/6.8 |
Erythromycin | ≤0.25 | >4 | 74.3/25.2 | 74.5/25.2 |
Clindamycin | ≤0.25 | ≤0.25 | 95.0/4.9 | 94.6/5.0 |
Gentamicin | ≤1 | ≤1 | 96.6/3.1 | 96.4/3.6 |
Tetracycline | ≤1 | ≤1 | 94.6/5.0 | 94.2/5.8 |
TMP/SMX | ≤0.5 | ≤0.5 | 98.7/1.3 | 98.7/1.3 |
The MIC interpretive criteria used were published by the CLSI (M100-S19) (3) and EUCAST (http://www.srga.org/eucastwt/MICTAB/index.html). The telavancin susceptibility breakpoint for S. aureus (≤1 μg/ml) was that recently approved by the U.S. FDA.
Values are in micrograms per milliliter.
—, no breakpoints available.